TORONTO, June 17, 2021 (GLOBE NEWSWIRE) — Psyence Group Inc. (“Psyence” or the “Company”) (PSYG:CSE), a public life science biotechnology company pioneering the use of natural psychedelics, is pleased to announce that through its wholly owned Jamaican subsidiary, Psyence Jamaica Limited (“Psyence Jamaica”), it has entered into a multi-year agreement (“Collaboration Agreement”) with the Jamaican…


Previous articleMINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression
Next articleRevive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics